Praxis Precision Medicines Inc

PRAX

290.100USD

-12.590-4.16%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

Praxis Precision Medicines Inc's Score

Industry at a Glance

Industry Ranking

83 / 391

Overall Ranking

196 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Praxis Precision Medicines Inc Highlights

StrengthsRisks

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -21.53, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 25.06M shares, decreasing 20.88% quarter-over-quarter.

Held by HOTCHKIS & WILEY

Star Investor HOTCHKIS & WILEY holds 140.00 shares of this stock.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

617.625

Target Price

+104.05%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Praxis Precision Medicines Inc is 6.42, ranking 249 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 51.52%.

Score

Industry at a Glance

Previous score

6.42

Change

0



Financials

6.95

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.21

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.17

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Praxis Precision Medicines Inc is 5.94, ranking 349 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -21.53, which is -99.28% below the recent high of -0.15 and -19.80% above the recent low of -25.79.

Score

Industry at a Glance

Previous score

5.94

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 83/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Praxis Precision Medicines Inc is 8.24, ranking 152 out of 391 in the Biotechnology & Medical Research industry. The average price target is 340.00, with a high of 760.00 and a low of 65.00.

Score

Industry at a Glance

Previous score

8.24

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Praxis Precision Medicines Inc is 6.89, ranking 118 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 326.74 and the support level at 269.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.33

Change

-0.44

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Praxis Precision Medicines Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 91.50%, representing a quarter-over-quarter decrease of 10.71%. The largest institutional shareholder is The Vanguard, holding a total of 1.46M shares, representing 5.23% of shares outstanding, with 1.75% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

2.76M

+9.10%

Perceptive Advisors LLC

1.56M

+14.83%

BlackRock Institutional Trust Company, N.A.

1.42M

+3.38%

The Vanguard Group, Inc.

Star Investors

1.26M

+4.11%

Baker Bros. Advisors LP

689.49K

--

Adage Capital Management, L.P.

1.31M

-45.02%

Cormorant Asset Management, LP

1.00M

-38.46%

Driehaus Capital Management, LLC

500.55K

-5.73%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Praxis Precision Medicines Inc is 2.04, ranking 253 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 3.01. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Praxis Precision Medicines Inc

PRAX

6.73 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment